Dose-controlled irradiation of cancer cells with laser-accelerated proton pulses
- 2.2k Downloads
Proton beams are a promising tool for the improvement of radiotherapy of cancer, and compact laser-driven proton radiation (LDPR) is discussed as an alternative to established large-scale technology facilitating wider clinical use. Yet, clinical use of LDPR requires substantial development in reliable beam generation and transport, but also in dosimetric protocols as well as validation in radiobiological studies. Here, we present the first dose-controlled direct comparison of the radiobiological effectiveness of intense proton pulses from a laser-driven accelerator with conventionally generated continuous proton beams, demonstrating a first milestone in translational research. Controlled dose delivery, precisely online and offline monitored for each out of ∼4,000 pulses, resulted in an unprecedented relative dose uncertainty of below 10 %, using approaches scalable to the next translational step toward radiotherapy application.
KeywordsProton Energy Relative Biological Effectiveness Radiochromic Film High Proton Energy Cell Irradiation
Cancer represents the second highest cause of death in industrial societies. Today, at a steadily increasing rate, already more than 50 % of all cancer patients are treated with photon or electron radiotherapy during the course of their disease. Radiotherapy by protons or heavier ion beams, due to their inverse depth dose profile (Bragg peak), can achieve better physical dose distributions than the most modern photon therapy approaches. In the case of ions heavier than protons, the higher relative biological effectiveness (RBE) [1, 2] might be of additional therapeutic benefit. It is estimated that at least 10–20 % of all radiotherapy patients may benefit from proton or light ion therapy [3, 4] and indications are currently evaluated in clinical trials worldwide. Yet, making widespread use of this potential calls for very high levels of clinical expertise and quality control as well as for enormous economical investment and running costs associated with large-scale accelerator facilities. The former point is presently being addressed in clinical research with, e.g., advanced real-time motion compensation techniques, while the latter requires more compact and cost-effective, yet, equally reliable particle accelerators.
As a promising alternative to conventional proton sources, compact laser plasma based accelerators have been suggested [5, 6, 7, 8, 9, 10, 11]. Practically, LDPR originates from hydrogenated contaminants on almost any solid target surface when irradiated with sufficiently intense ultra-short-pulse laser light . Electrons are heated to megaelectronvolt temperatures during the interaction, and driven out of the target volume. In the corresponding electric field, yielding unsurpassed gradients in the megavolt per micrometer range, protons at the surface efficiently gain initial energy . Over the last decade, intense proton pulses with energies exceeding several 10 MeV have been reached with large single-shot laser facilities. Yet, only with the recent generation of table-top 100 TW Ti:Sapphire lasers, operating at pulse repetition rates of up to 10 Hz, energies exceeding 10 MeV [14, 15, 16, 17, 18] became accessible for applications where also the average dose rate is of interest, e.g., for providing sufficiently short treatment durations of a few minutes. For the anticipated future application in radiation therapy, a further increase in the proton energy of up to 200–250 MeV is required, which is currently addressed by the investigation of novel acceleration schemes [19, 20, 21] as well as by ongoing laser development.
Equally indispensable for the development of devices suitable for radiobiological studies and clinical applications is the competitiveness of the laser plasma accelerator with conventional sources in terms of precision, reliability and reproducibility. Research in this field can adequately be performed with available technology and, in particular, presently accessible particle energies as introduced in Ref. . The challenge is the development of a laser-based treatment facility taking into account the specific properties of LDPR, in particular, the comparatively broad energy spectrum and the distribution of the therapeutically required dose in a finite number of very intense pulses, where the level of the peak dose rate in one pulse can exceed the average by up to nine orders of magnitude. This task has to be addressed by translational research, meaning the transfer of the results of the complex and interdisciplinary basic research into clinical practice , starting from in vitro cell irradiation, over experiments with animals, to clinical studies. Vice versa the realization of each translational step represents a benchmark of the development status of the laser-driven dose-delivery system to a clinically applicable beam, being the main objective of our work.
In this sense, in this article, we directly compare the RBE of pulsed LDPR and conventionally accelerated continuous proton beams in vitro demonstrating scalable controlled dose-delivery and clinical precision standards for both sources. This work is building on previous work from our group  and the radiobiological results are consistent with first experiments performed by Yogo et al. [24, 25] and a recent single-pulse study of the RBE by Doria et al.  with retrospective dose evaluation.
2 Setup of the laser-driven proton dose-delivery system
Directly behind the target the energetic protons pass through a magnetic dipole filter  applied to clean the pulse of all protons with energies below 8 MeV. Intrinsically, the direct line-of-sight between the interaction point and the irradiation site is blocked and thus secondary radiation generated in the laser plasma is suppressed. Downstream of the magnetic filter the integrated dosimetry and cell irradiation system (IDOCIS) is located [22, 28]. Its interior components for dosimetry and cell irradiation are separated from the vacuum of the target chamber by a thin plastic window. The IDOCIS module integrates a thin transmission ionization chamber for real-time control of dose delivery and a cell holder inset. The latter can be replaced by several reference dosimeters such as a Faraday cup (FC, design adopted from Ref. ), radiochromic films (RCF), or CR39 solid state nuclear track detectors to determine the applied 2D dose and spectral energy distribution in the plane of the cell monolayer. For that purpose, an absolute calibration for RCF and FC detectors was carried out before performing the irradiation experiments with laser-accelerated protons for proton energies of 5–60 MeV at the eye tumor therapy centre of the Helmholtz Zentrum Berlin (HZB), Germany . The ionization chamber optimized for lowest ion energies, thus consisting of three metalized kapton foils (each only 7.5-μm thick), is permanently placed in front of the different insets and is used to establish the relationship between FC and RCF and to the real-time control of the dose delivery. It is therefore cross-calibrated to FC and RCF before and after each cell irradiation taking saturation effects at high dose rates into consideration (similar to Ref. ).
During the irradiation dose homogenization on a 2 × 6 mm2 spot size is ensured by multiple rotations of the cell sample. The optimization and control of the homogenous 2D dose distribution in the plane of the cell monolayer and the estimation of the contribution of the inhomogeneity (below 5 %) to the dose error was performed with RCF and CR39 nuclear track detectors.
For the control of the dose deposited into the thin cell monolayer, the proton energy spectrum has to be known. Figure 1 (right) shows a typical normalized spectrum at the cell location deduced from Thomson parabola measurements recorded directly before the cell irradiation campaign and including the transmission of the energy selective beam delivery . During the irradiation experiments, stacks of RCF and CR39, providing a coarse energy resolution due to the energy-range relationship of the stopping power, were used to cross-check the applied energy spectrum in the plane of the cell monolayer and complemented by the online observation of the stability of the spectral filtering with a plastic scintillator positioned between the dipole filter and the IDOCIS entrance pinhole.
In the presented experimental campaign, the use of sufficiently high proton energies at the cell layer position (>6.5 MeV) ensured a constant linear energy transfer (LET). Therefore, significantly less uncertainty in the energy-dependent energy loss was achieved than if the Bragg peak was be positioned at the depth of the cell monolayer. This method yields the most reliable exposure range for systematic studies as illustrated by the normalized energy deposition for the representative energies of 7, 8.5, and 12 MeV as a function of the depth in water depicted below the spectrum in Fig. 1.
3 Dose effect curves and dose uncertainty
For the irradiation experiment, the radiosensitive human squamous cell carcinoma cell line SKX was used . Cells were seeded 1 day before irradiation on a thin biofilm as bottom of a chamber slide. The plating efficiency was in the range of 15–20 %. Before irradiation, 1 ml of cell culture medium was added, the well was closed with sterile parafilm and the sample was positioned in the horizontal LDPR beam. Further details on derivation, cultivation and handling of the cell line as well as applied sample geometries are provided in Refs. [22, 32, 33]. The cells were irradiated with a mean dose of 81 mGy per shot that corresponds to a peak dose rate for each proton bunch of 4 × 107 Gy/s. The dose was applied in the range between 0.5 and 4.3 Gy (0.43 Gy/min averaged over 1 min) and controlled by means of the ionization chamber in front of the cells.
The biological endpoint of the yield of residual DNA double-strand breaks (DSB) remaining 24 h after irradiation was analysed. It has been shown previously for this cell line that residual DNA DSB correlate closely with cell survival . The DNA DSB were detected by means of fluorescent-labeled antibodies against the active forms of histone γ-H2AX  and protein 53BP1 . Both molecules were activated and related to the position of radiation-induced DNA DSB [35, 36]. The average number of radiation-induced DNA DSB per cell nucleus was counted for each irradiated cell sample and evaluated as a function of the applied dose.
An in-house tandem Van-de-Graaf accelerator served as reference radiation source providing 7.2 MeV protons delivered as a continuous beam with a dose rate of 1.1 Gy/min in a homogeneous beam spot of 35 mm2. The equipment and the dosimetry methods, e.g., including IDOCIS module and detectors, horizontal beam application, etc., were identical for both radiation sources (more details in Ref. ). As the irradiation setup was initially developed for the polychromatic beam of the laser plasma accelerator, no additional filtering was applied for the case of the mono-energetic tandem beam. For the dosimetry, the spectrum has no further implications, because the cell sample is positioned ahead of the Bragg peak (Fig. 1). Moreover, the location of both radiation sources and a cell laboratory on one site guarantees the direct comparability of radiobiological outcome for laser-driven and conventionally accelerated proton beams. To connect the successive experimental campaigns (LDPR and conventionally accelerated protons), and to identify possible deviations in the biological response arising from biological diversity, reference irradiations with standard 200-kV X-rays (filtered with 7 mm Be and 0.5 mm Cu) were performed in parallel to each proton experiment.
The key to this with respect to LDPR unprecedented level of precision is the synergetic combination of first, the reduction of the uncertainty in the dose delivery caused by beam fluctuations and detector responses using two independent absolute dose formalisms, and second, the reliable operation of the laser-driven proton source based on well-controlled laser conditions on target.
The measurement of the precise dose applied to the cell monolayer is based on the implementation of radiochromic films and a Faraday cup into the irradiation site as two distinct, dose rate independent, and absolutely calibrated dosimetry systems. Using these systems, the absolute dose value and the relative dose uncertainty were determined for each irradiated cell sample individually by repeated cross-calibration of the real-time monitor signal of the transmission ionization chamber to RCF and FC directly before and after each irradiation. Performing a weighted average of the RCF and FC signals in combination with the use of sufficiently high proton energies at the cell monolayer position (>6.5 MeV) allowed for this significant reduction of the measurement uncertainty.
4 Conclusions and outlook
Summarizing, laser-driven dose-delivery systems dedicated for the in vitro cell irradiation with proton pulses can be operated at a performance level that is sufficient for radiobiological studies on short as well as on long time-scales and with a precise delivery of prescribed doses. Methods and components of the presented approach such as real-time transmission dose monitoring can be directly scaled to higher proton energies, later required for proton cancer therapy. This performance level has been validated by the independent measurement of two dose effect curves based on different endpoints.
Both radiobiological results are in good agreement with a complementary experiment performed at the Munich Tandem Van-de-Graaf accelerator [37, 38] and a recent study of the RBE of intense single pulses of LDPR, where the dose applied to the cells was varying across the probe and analyzed retrospectively for individual irradiated areas . Making use of different pulse modes of the Tandem accelerator, the first study focused on the dependence of the RBE on the peak dose rate by comparing the effect of short-pulses (few nanoseconds) and continuous beams of 20 MeV protons, while the latter directly made use of the intrinsically high peak dose rates of LDPR of up to few Gy per pulse. It thus seems that all existing studies performed for different cell-lines and making use of different sources confirm that in the therapeutically relevant dose range of a few Gy, even if applied in a single pulse of only few nanoseconds duration, non-linear radiobiological effects due to simultaneous multiple damages in cells and, thus, below any time-scale of repair mechanisms are unlikely to arise.
The next step in translational research will be the extension of the experiments to volume irradiation in animal experiments. In comparison to the studies on biological effects in two-dimensional cell monolayers, these experiments are more complex and require not only higher but also tunable proton energies.
In addition, the cell irradiation setup presented in Fig. 1 is extended by a pulsed solenoid providing a high capture and transport efficiency of up to 20–25 % measured in . By tuning the delay between laser pulse and solenoid trigger in a multi-shot approach, the energy-dependent beam collimation allows for the active shaping of the spectral intensity of the proton energy spectrum given for the cell location in Fig. 1. Thus, a homogeneous proton depth dose distribution (spread-out Bragg peak) can be applied to the tumor without the need to shape the energy distribution in the plasma acceleration process.
The demonstrated advances in the performance of compact laser-driven proton sources and dedicated dosimetric techniques not only represent an important milestone on the way to the realization of a clinical laser-based proton treatment facility but also open the door to further applications where ultra-fast and reliable sources are required.
The authors want to thank M. Sobiella, J. Woithe and Y. Dammene for the technical support and E. Lessmann for the work in the cell laboratory. We acknowledge S. Bock and U. Helbig for providing excellent laser support. The work has been supported by the German Federal Ministry of Education and Research (BMBF) under contract number 03ZIK445.
- 3.M.H. Baron, P. Pommier, V. Favrel, G. Truc, J. Balosso, J. Rochat, ETOILE project, A “One-day survey”: as a reliable estimation of the potential recruitment for proton- and carbon-ion therapy in France. Radiother. Oncol. 73, 15–17 (2004)Google Scholar
- 4.R. Mayer, U. Mock, R. Jager, R. Potter, C. Vutuc, H. Eiter, K. Krugmann, J. Hammer, B. Hirn, R. Hawliczek, T.H. Knocke-Abulesz, P. Lukas, E. Nechville, B. Pakisch, M. Papauschek, R. Wolfgang, W. Rhomberg, H. Sabitzer, A. Schratter-Sehn, S. Felix, I. Wedrich, T. Auberger, Epidemiological aspects of hadron therapy: a prospective nationwide study of the Austrian project MedAustron and the Austrian Society of Radiooncology (OEGRO). Radiother. Oncol. 73, 24–28 (2004)Google Scholar
- 15.F. Dollar, T. Matsuoka, G.M. Petrov, A.G.R. Thomas, S.S. Bulanov, V. Chvykov, J. Davis, G. Kalinchenko, C. McGuffey, L. Willingale, V. Yanovsky, A. Maksimchuk, K. Krushelnick, Control of energy spread and dark current in proton and ion beams generated in high-contrast laser solid interactions. Phys. Rev. Lett. 107, 065003 (2011)ADSCrossRefGoogle Scholar
- 16.A. Henig, S. Steinke, M. Schnürer, T. Sokollik, R. Hörlein, D. Kiefer, D. Jung, J. Schreiber, B.M. Hegelich, X.Q. Yan, J. Meyer-ter Vehn, T. Tajima, P.V. Nickles, W. Sandner, D. Habs, Radiation-pressure acceleration of ion beams driven by circularly polarized laser pulses. Phys. Rev. Lett. 103, 245003 (2009)ADSCrossRefGoogle Scholar
- 17.R. Prasad, S. Ter-Avetisyan, D. Doria, K.E. Quinn, L. Romagnani, P.S. Foster, C.M. Brenner, J.S. Green, P. Gallegos, M.J.V. Streeter, D.C. Carroll, O. Tresca, N.P. Dover, C.A.J. Palmer, J. Schreiber, D. Neely, Z. Najmudin, P. McKenna, M. Zepf, M. Borghesi, Proton acceleration using 50 fs, high intensity astra-gemini laser pulses. Nucl. Instrum. Methods Phys. Res. Sect. A Accel. Spectrom. Detect. Assoc. Equip. 653, 113–115 (2011)ADSCrossRefGoogle Scholar
- 18.K. Ogura, M. Nishiuchi, A.S. Pirozhkov, T. Tanimoto, A. Sagisaka, T. Zh. Esirkepov, M. Kando, T. Shizuma, T. Hayakawa, H. Kiriyama, T. Shimomura, S. Kondo, S. Kanazawa, Y. Nakai, H. Sasao, F. Sasao, Y. Fukuda, H. Sakaki, M. Kanasaki, A. Yogo, S.V. Bulanov, P.R. Bolton, K. Kondo, Proton acceleration to 40 MeV using a high intensity, high contrast optical parametric chirped-pulse amplification/Ti:sapphire hybrid laser system. Opt. Lett. 37, 2868–2870 (2012)ADSCrossRefGoogle Scholar
- 20.S. Buffechoux, J. Psikal, M. Nakatsutsumi, L. Romagnani, A. Andreev, K. Zeil, M. Amin, P. Antici, T. Burris-Mog, A. Compant-La-Fontaine, E. d’Humières, S. Fourmaux, S. Gaillard, F. Gobet, F. Hannachi, S. Kraft, A. Mancic, C. Plaisir, G. Sarri, M. Tarisien, T. Toncian, U. Schramm, M. Tampo, P. Audebert, O. Willi, T.E. Cowan, H. Pépin, V. Tikhonchuk, M. Borghesi, J. Fuchs, Hot electrons transverse refluxing in ultraintense laser-solid interactions. Phys. Rev. Lett. 105, 015005 (2010)ADSCrossRefGoogle Scholar
- 21.S.A. Gaillard, T. Kluge, K.A. Flippo, M. Bussmann, B. Gall, T. Lockard, M. Geissel, D.T. Offermann, M. Schollmeier, Y. Sentoku, T.E. Cowan, Increased laser-accelerated proton energies via direct laser-light-pressure acceleration of electrons in microcone targets. Phys. Plasmas 18, 056710 (2011)ADSCrossRefGoogle Scholar
- 22.S.D. Kraft, C. Richter, K. Zeil, M. Baumann, E. Beyreuther, S. Bock, M. Bussmann, T.E. Cowan, Y. Dammene, W. Enghardt, U. Helbig, L. Karsch, T. Kluge, L. Laschinsky, E. Lessmann, J. Metzkes, D. Naumburger, R. Sauerbrey, M. Schürer, M. Sobiella, J. Woithe, U. Schramm, J. Pawelke, Dose-dependent biological damage of tumour cells by laser-accelerated proton beams. N. J. Phys. 12, 085003 (2010)CrossRefGoogle Scholar
- 23.M. Baumann, S.M. Bentzen, W. Doerr, M.C. Joiner, M. Saunders, I.F. Tannock, H.D. Thames. The translational research chain: is it delivering the goods? Int. J. Radiat. Oncol. Biol. Phys. 49,345–351 (2001)Google Scholar
- 24.A. Yogo, K. Sato, M. Nishikino, M. Mori, T. Teshima, H. Numasaki, M. Murakami, Y. Demizu, S. Akagi, S. Nagayama, K. Ogura, A. Sagisaka, S. Orimo, M. Nishiuchi, A.S. Pirozhkov, M. Ikegami, M. Tampo, H. Sakaki, M. Suzuki, I. Daito, Y. Oishi, H. Sugiyama, H. Kiriyama, H. Okada, S. Kanazawa, S. Kondo, T. Shimomura, Y. Nakai, M. Tanoue, H. Sasao, D. Wakai, P.R. Bolton, H. Daido, Application of laser-accelerated protons to the demonstration of DNA double-strand breaks in human cancer cells. Appl. Phys. Lett. 94, 181502 (2009)ADSCrossRefGoogle Scholar
- 25.A. Yogo, T. Maeda, T. Hori, H. Sakaki, K. Ogura, M. Nishiuchi, A. Sagisaka, H. Kiriyama, H. Okada, S. Kanazawa, T. Shimomura, Y. Nakai, M. Tanoue, F. Sasao, P.R. Bolton, M. Murakami, T. Nomura, S. Kawanishi, K. Kondo, Measurement of relative biological effectiveness of protons in human cancer cells using a laser-driven quasimonoenergetic proton beamline. Appl. Phys. Lett. 98, 053701 (2011)ADSCrossRefGoogle Scholar
- 26.D. Doria, K.F. Kakolee, S. Kar, S.K. Litt, F. Fiorini, H. Ahmed, S. Green, J.C.G. Jeynes, J. Kavanagh, D. Kirby, K.J. Kirkby, C.L. Lewis, M.J. Merchant, G. Nersisyan, R. Prasad, K.M. Prise, G. Schettino, M. Zepf, M. Borghesi. Biological effectiveness on live cells of laser driven protons at dose rates exceeding 109 Gy/s. AIP 2, 011209 (2012)Google Scholar
- 27.J. Metzkes, T.E. Cowan, L. Karsch, S.D. Kraft, J. Pawelke, C. Richter, T. Richter, K. Zeil, U. Schramm, Preparation of laser-accelerated proton beams for radiobiological applications. Nucl. Instrum. Methods Phys. Res. Sect. A Accel. Spectrom. Detect. Assoc. Equip. 653, 172–175 (2011)ADSCrossRefGoogle Scholar
- 31.U. Kasten-Pisula, A. Menegakis, I. Brammer, K. Borgmann, W.Y. Mansour, S. Degenhardt, M. Krause, A. Schreiber, J. Dahm-Daphi, C. Petersen, E. Dikomey, M. Baumann, The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair. Radiother. Oncol. 90, 257–264 (2009)CrossRefGoogle Scholar
- 33.L. Laschinsky, M. Baumann, E. Beyreuther, W. Enghardt, M. Kaluza, L. Karsch, E. Lessmann, D. Naumburger, M. Nicolai, C. Richter, R. Sauerbrey, H.P. Schlenvoigt, J. Pawelke, Radiobiological effectiveness of laser accelerated electrons in comparison to electron beams from a conventional linear accelerator. J. Radiat. Res. 53, 395–403 (2012) Google Scholar
- 34.A. Menegakis, A. Yaromina, W. Eicheler, A. Dörfler, B. Beuthien-Baumann, H.D. Thames, M. Baumann, M. Krause, Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by γH2AX staining. nt. J. Radiat. Biol. 85, 1032–1041 (2009)CrossRefGoogle Scholar
- 38.O. Zlobinskaya, G. Dollinger, D. Michalski, V. Hable, C. Greubel, G. Du, G. Multhoff, B. Röper, M. Molls, T. Schmid, Induction and repair of DNA double-strand breaks assessed by gamma-H2AX foci after irradiation with pulsed or continuous proton beams. Radiat. Environ. Biophys. 51, 23–32 (2012)CrossRefGoogle Scholar
- 39.T. Burris-Mog, K. Harres, F. Nürnberg, S. Busold, M. Bussmann, O. Deppert, G. Hoffmeister, M. Joost, M. Sobiella, A. Tauschwitz, B. Zielbauer, V. Bagnoud, T. Herrmannsdoerfer, M. Roth, T.E. Cowan, Laser accelerated protons captured and transported by a pulse power solenoid. Phys. Rev. Special Top. Accel. Beams 14, 121301 (2011)ADSCrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.